KRYS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KRYS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Krystal Biotech's Dividends per Share for the three months ended in Jun. 2024 was $0.00.
The historical rank and industry rank for Krystal Biotech's 3-Year Dividend Growth Rate or its related term are showing as below:
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
Krystal Biotech's Dividend Payout Ratio for the three months ended in Jun. 2024 was 0.00. As of today, Krystal Biotech's Dividend Yield % is 0.00%.
For more information regarding to dividend, please check our Dividend Page.
For the Biotechnology subindustry, Krystal Biotech's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Krystal Biotech's 3-Year Dividend Growth Rate distribution charts can be found below:
* The bar in red indicates where Krystal Biotech's 3-Year Dividend Growth Rate falls into.
This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
Krystal Biotech (NAS:KRYS) 3-Year Dividend Growth Rate Explanation
1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.
Krystal Biotech's Dividend Payout Ratio for the quarter that ended in Jun. 2024 is calculated as
Dividend Payout Ratio | = | Dividends per Share (Q: Jun. 2024 ) | / | EPS without NRI (Q: Jun. 2024 ) |
= | 0 | / | 0.939 | |
= | 0.00 |
2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krish S Krishnan | director, 10 percent owner, officer: President and CEO | 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203 |
Suma Krishnan | director, 10 percent owner, officer: Chief Operating Officer | 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203 |
Julian S Gangolli | director | 4955 BASELINE AVENUE, SANTA YNEZ CA 93460 |
Kathryn Romano | officer: Chief Accounting Officer | C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203 |
Catherine Mazzacco | director | C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203 |
Daniel Janney | director | PO BOX 7414, JACKSON WY 83002 |
Andrew C. Orth | officer: Chief Commercial Officer | 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203 |
Dino A Rossi | director | 61 WATROO POINT, DANIEL ISLAND SC 29492 |
Everett Rand Sutherland | director | 29 HARTWELL AVENUE, LEXINGTON MA 02421 |
Christopher Mason | director | C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203 |
Jing L. Marantz | director | C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203 |
Jennifer Chien | officer: Chief Commercial Officer | C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203 |
Antony A Riley | officer: Chief Financial Officer | C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 94538 |
R Douglas Norby | director | C/O MAGNACHIP SEMICONDUCTOR, INC., 20400 STEVENS CREEK BOULEVARD, SUITE 370, CUPERTINO CA 95014 |
Sun Pharma (netherlands) B.v. | 10 percent owner | POLARISAVENUE 87, 2132 JH HOOFDDORP P7 00000 |
From GuruFocus
By GuruFocus Research • 02-07-2024
By Marketwired • 09-13-2024
By GuruFocus Research • 02-28-2024
By GuruFocus Research • 08-06-2024
By GuruFocus Research • 05-07-2024
By Marketwired • 04-22-2024
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-29-2024
By Marketwired • 08-05-2024
By GuruFocus Research • 05-07-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.